Sildenafil
- 3 independent labs in 4 countries
- Funder: Norges Forskningsråd
- Humans1
- Animals1
Outcomes
3Amyloid plaques
downin mice1
1 study
Amyloid plaques
downin mice1
Sildenafil decreases amyloid plaques in mice.
“Immunostaining revealed significantly decreased amyloid plagues in the isocortex and interbrain of the sildenafil‐treated mice”
Animalsbrain15 mg/kg3 months
AAIC 2025 abstract26 Dec 2025
Cognitive function
upin mice1
1 study
Cognitive function
upin mice1
Sildenafil improves cognitive function in mice.
“Sildenafil treatment in mice significantly improved novel object recognition and performance on the Morris water maze and contextual fear conditioning test.”
Animals15 mg/kg3 months
AAIC 2025 abstract26 Dec 2025
Fenestration frequency
upin mouse cells1
1 study
Fenestration frequency
upin mouse cells1
Sildenafil increases fenestration frequency in mouse cells (3-fold lower concentration).
“Sildenafil PACA reversed age-related changes LSEC fenestration frequency and porosity at 3-fold lower sildenafil concentrations than sildenafil alone.”
Cellsliver
Nanotheranostics14 May 2025
Associations
1Alzheimer's disease
downin humans2HR 0.47
2 studies
Alzheimer's disease
downin humans2HR 0.47
Sildenafil lowers the risk of Alzheimer's disease in humans.
“Compared to spironolactone, sildenafil was linked with a 46% and 30% reduced prevalence of AD in MarketScan (HR = 54%, 95% CI 0.32‐0.66, p ‐value = 3.33x10‐5)”
Humanscompared to spironolactone
AAIC 2025 abstract26 Dec 2025
Sildenafil lowers the risk of Alzheimer's disease in humans (HR 0.47, 95% CI 0.27-0.82, p<0.001).
“Sildenafil use was associated with a reduced risk of developing AD by two-fold compared to non-use (HR: 0.47, 95% CI: 0.27-0.82, p<0.001).”
Review
Sildenafil and risk of Alzheimer disease: a systematic review and meta-analysis
Aging17 Mar 2025